ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI)
Publication
, Conference
Scher, HI; Fizazi, K; Saad, F; Chi, K; Taplin, M; Sternberg, CN; Armstrong, AJ; Hirmand, M; Selby, B; de Bono, JS
Published in: ANNALS OF ONCOLOGY
September 1, 2012
Duke Scholars
Published In
ANNALS OF ONCOLOGY
ISSN
0923-7534
Publication Date
September 1, 2012
Volume
23
Start / End Page
297 / 297
Location
Vienna, AUSTRIA
Publisher
OXFORD UNIV PRESS
Conference Name
37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Scher, H. I., Fizazi, K., Saad, F., Chi, K., Taplin, M., Sternberg, C. N., … de Bono, J. S. (2012). ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI). In ANNALS OF ONCOLOGY (Vol. 23, pp. 297–297). Vienna, AUSTRIA: OXFORD UNIV PRESS.
Scher, H. I., K. Fizazi, F. Saad, K. Chi, M. Taplin, C. N. Sternberg, A. J. Armstrong, M. Hirmand, B. Selby, and J. S. de Bono. “ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI).” In ANNALS OF ONCOLOGY, 23:297–297. OXFORD UNIV PRESS, 2012.
Scher HI, Fizazi K, Saad F, Chi K, Taplin M, Sternberg CN, et al. ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI). In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2012. p. 297–297.
Scher, H. I., et al. “ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI).” ANNALS OF ONCOLOGY, vol. 23, OXFORD UNIV PRESS, 2012, pp. 297–297.
Scher HI, Fizazi K, Saad F, Chi K, Taplin M, Sternberg CN, Armstrong AJ, Hirmand M, Selby B, de Bono JS. ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI). ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2012. p. 297–297.
Published In
ANNALS OF ONCOLOGY
ISSN
0923-7534
Publication Date
September 1, 2012
Volume
23
Start / End Page
297 / 297
Location
Vienna, AUSTRIA
Publisher
OXFORD UNIV PRESS
Conference Name
37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis